CLIA: 39D2085645
New York State has a separate and unique regulatory approval process for laboratory diagnostic testing. PeriRx is currently in the application process with our SaliMark™ OSCC test and is vigorously committed to pursuing this application approval.
PeriRx Investigates Salivary Tests for Lung Cancer
Oral cancer kills more than 8,650 people each year in the United States, largely due to late diagnosis. PeriRx aims to fight those numbers with its SaliMark OSCC salivary test, which catches cancer in its earliest stages. Now the company has set its experience in salivary diagnoses on a larger target with much more at stake—lung cancer and the more than 150,ooo people it kills each year. [Read more…]